Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024Business Wire • 08/26/24
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register NowGlobeNewsWire • 08/20/24
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/12/24
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall StreetInvestorPlace • 06/13/24
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceBusiness Wire • 05/14/24
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/07/24
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsBusiness Wire • 05/06/24
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineBusiness Wire • 05/03/24
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/05/24
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023Business Wire • 12/13/23
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of DirectorsBusiness Wire • 11/29/23
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 11/09/23